In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

"Shareholder Value Destruction" following Tiger scandal

This article was originally published in The Rose Sheet

Executive Summary

New report from the University of California, Davis, focuses not on Tiger Woods' future earning potential, but instead "estimate[s] losses that may be larger, more widely felt, and more immediate: those incurred by shareholders of the firms paying Mr. Woods to endorse their products." Professors Christopher R. Knittel and Victor Stango figure that shareholders of companies that sponsored the pro golfer lost $5 bil.-$12 bil. in wealth in the two weeks between Woods' car accident and announced leave-taking from golf. Losses were measured "relative to both the entire stock market and a set of competitor firms," they note. Woods' top five sponsors - P&G's Gillette, Accenture, Nike, Electronic Arts and Gatorade - each lost 2%-3% of their aggregate market value after the car accident, the authors assert. Gillette announced Dec. 12 it would "limit" Woods' role in marketing and promotional efforts (1"The Rose Sheet" Dec. 21, 2009)

You may also be interested in...



Gillette Downsizes Tiger Woods' Marketing Role

Procter & Gamble/Gillette says it will curtail its use of golf superstar Tiger Woods in promotions

News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR

This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.

Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups

Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016646

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel